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Thoracic malignancies, especially lung cancer and malignant
pleural mesothelioma (MPM), account for a huge disease burden
with devastating mortality worldwide. The unprecedented ad-
vances in the development of anticancer therapies in the past few
years reﬂect the importance of precision medicine. For advanced
non–small-cell lung cancer (NSCLC), the current standard of care
is to determine the presence of actionable targets, such as epi-
dermal growth factor receptor mutations and anaplastic lym-
phoma kinase rearrangement, that allow logical use of speciﬁc
targeted therapies.1-4 Recent data also support the upfront use of
immuno-oncologic agents (pembrolizumab, an anti–programmed
death 1 or PD1 antibody) among the subgroup of patients with
advanced NSCLC that strongly expresses PD-L1.5 In contrast,
the current standard therapeutic options for advanced MPM are
limited, with pemetrexed platinum doublet as the standard of care,
whereas emerging data support the potential role of bevacizumab6
and immuno-oncologic agents7 in recent years. An urgent need
still exists for novel and personalized cancer therapeutics in both
advanced lung cancer and MPM.
In the article that accompanies this editorial, Beddowes et al8
report a phase I trial of pegylated arginine deiminase (ADI-PEG
20), cisplatin, and pemetrexed in nine patients with advanced
NSCLC or MPM who are deﬁcient in argininosuccinate synthetase
1 (ASS1). Because ASS1 is the key enzyme involved in the urea cycle
for biosynthesis of arginine, tumors deﬁcient in ASS1 are pre-
dictably susceptible to therapeutic arginine depletion (ie, arginine
auxotrophic) with agents like ADI-PEG 20. Apart from de-
termining the recommended dose of ADI-PEG 20 for future study,
this small phase I study also provides a glimpse of the clinical
activity of this combination, especially in MPM. The approach in
selecting tumors on the basis of ASS1 expression by immuno-
histochemistry (IHC) is biologically sound. However, because IHC
expression of ASS1 is a continuum rather than a dichotomized
biomarker, the exact cutoff values need to be clinically determined.
Beddowes et al8 deﬁned ASS1 deﬁciency by 0 or 11 IHC staining
in. 50% tumor cells, which is based on preclinical studies.9,10 The
same deﬁnition of ASS1 deﬁciency has also been adopted in the
Arginine Deiminase and Mesothelioma (ADAM) study, which
reported favorable progression-free survival with ADI-PEG 20
monotherapy compared with best supportive care in ASS1-
deﬁcient MPM.11 Nonetheless, the appropriate and clinically
relevant cutoff that deﬁnes ASS1 deﬁciency requires a robust
clinical investigation that preferably involves separate training and
validation cohorts, which is lacking at the moment. The biologic
response to arginine depletion also may vary between tumors, and
whether the same cutoff can be used in different tumor types
remains to be determined.
The main limitation that precludes sustained response to
ADI-PEG 20 is the development of a neutralizing antibody. In the
ADAM study with monotherapy of ADI-PEG 20 in MPM, ap-
proximately two thirds of patients developed an anti–ADI-PEG 20
antibody, which resulted in a rebound increase in plasma arginine
level by the third month of treatment.11 Similarly, a previous phase I
study of the combination of ADI-PEG 20 and docetaxel in various
advanced solid tumors also detected autoantibodies to ADI-PEG
20 as early as 6 weeks after treatment, which resulted in a gradual
return to baseline levels of plasma arginine.12 On the other hand,
no neutralizing antibody production against ADI-PEG 20 was
observed in early clinical trials in melanoma13 and hepatocellular
carcinoma.14 Of note, Beddowes et al8 show that the combination
of ADI-PEG 20, cisplatin, and pemetrexed can rapidly deplete
plasma arginine levels and sustain these levels throughout the
18 weeks of treatment, although no data during ADI-PEG 20
monotherapy beyond the combination phase are reported. This
ﬁnding is corroborated by the detection of a neutralizing antibody
against ADI-PEG 20 by 8 to 10 weeks at low titers until 18 weeks of
treatment. The exact explanation for the low level of antidrug
antibody with this combination, in contrast to monotherapy with
ADI-PEG 20 in the ADAM study,11 needs to be further elucidated
but could be related to the use of corticosteroid premedication,
chemotherapy-speciﬁc effects, or simply chance as a result of the
small sample size.8 Future development of arginine depletion
therapy with ADI-PEG 20 will hinge on the effective ways to
prevent the production of neutralizing antidrug antibody.
Although one should avoid overemphasis of the clinical ef-
ﬁcacy observed in a small-scale phase I study, Beddowes et al8
report a notable objective response rate of 78% with the combi-
nation therapy, which is unusual for biphasic and sarcomatoid
MPM, and these encouraging results warrant conﬁrmation in
future large-scale randomized controlled trials. Compared with
data from the ADAM study, the best response attained with ADI-
PEG 20 monotherapy at 4 months was only disease stabilization
despite a predominance of nonsarcomatoid histology of MPM,11
which could be partly due to the rapid emergence of antidrug
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antibody that led to unsustained depletion of plasma arginine
in the majority of subjects. Because continuation maintenance
therapy with pemetrexed is an established standard of care in
advanced nonsquamous NSCLC, future clinical trials also should
explore the role of a maintenance doublet with ADI-PEG 20 and
pemetrexed for patients who respond to triplet induction therapy.
In the ADAM study, some concerns exist about the safety of
ADI-PEG 20 treatment, which was associated with grade 3 ana-
phylaxis in four patients (9%) and with serum sickness in two.11
However, in the study by Beddowes et al,8 the combination of ADI-
PEG 20, cisplatin, and pemetrexed was well tolerated. In the only
patient who experienced an infusion-related adverse effect, the hy-
persensitivity reaction was ascribed to cisplatin rather than to ADI-
PEG 20. If this reaction is conﬁrmed in future large-scale clinical
trials, corticosteroid premedication similar to the usual premed-
ication for pemetrexed should be considered for ADI-PEG 20 therapy.
Following in the footsteps of L-asparaginase in the treatment of
acute lymphoblastic leukemia, arginine depletion therapy has now
emerged as a novel therapeutic for biomarker-selected thoracic ma-
lignancies. Future development of ADI-PEG 20 as an arginine depletor
with or without systemic chemotherapy will add to the growing ar-
mamentarium in the ﬁght against advanced lung cancer and MPM.
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